Tucker Joseph Edward

SEC source: 0001883914-26-000003 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,479

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001193125-26-209581 · ownership.xml · derivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,784

Underlying: Common Stock · 33,784 shares

Expires 2036-04-23

F1 · derivative.exercise_date: The warrants vest in four equal tranches of 8,446 warrants each on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028.

SEC source: 0001193125-25-337175 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,355

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-25-012677 · form4-05122025_050501.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,711

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001415889-24-025052 · form4-10112024_111058.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,829

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001415889-24-005259 · form4-02262024_090238.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,196

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

SEC source: 0001493152-23-002799 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,196

F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.

SEC source: 0001493152-23-002453 · ownership.xml · nonDerivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,196

F3 · shares: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and 143.50, respectively.

F2 · balance_after: Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-23-002453 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,196

F1 · shares: The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively.

F2 · balance_after: Includes 13,822 shares previously held through the Tucker 2020 Family Trust, which were distributed to the reporting person and are now owned directly.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 4

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,290

Underlying: Common Stock · 13,290 shares

Expires 2023-09-16

F6 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F8 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 3

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 664,503

Underlying: Common Stock · 664,503 shares

Expires 2025-05-26

F6 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F7 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-023865 · ownership.xml · derivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,351

Underlying: Common Stock · 199,351 shares

Expires 2026-04-05

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.

F5 · price: Received in exchange for options to acquire 750,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.

SEC source: 0001493152-21-023865 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 691,083

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust controlled by Dr. Tucker.

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 4

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footenote

Disclosed balance after: 13,290

Underlying: Common Stock · 13,290 shares

Expires 2023-09-16

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F7 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 3

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footenote

Disclosed balance after: 531,602

Underlying: Common Stock · 531,602 shares

Expires 2025-05-26

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F6 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.

SEC source: 0001493152-21-025237 · ownership.xml · derivative · entry 2

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,901

Underlying: Common Stock · 132,901 shares

Expires 2025-05-26

F4 · price: Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.

F5 · price: The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

SEC source: 0001493152-21-025237 · ownership.xml · nonDerivative · entry 1

Tucker Joseph Edward · CIK 0001883914 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 691,083

F1 · price: Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.

F2 · price: Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.

F3 · ownership.nature: Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.